{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T09:35:22Z","timestamp":1793957722290,"version":"4.8.0"},"reference-count":34,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"<jats:sec id=\"ab-zoi221191-4\"><jats:title>Importance<\/jats:title><jats:p>Herpes zoster infection after COVID-19 vaccination has been reported in numerous case studies. It is not known whether these cases represent increased reporting or a true increase in risk.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi221191-5\"><jats:title>Objective<\/jats:title><jats:p>To assess whether COVID-19 vaccination is associated with an increased risk of herpes zoster infection.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi221191-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This cohort study used a self-controlled risk interval (SCRI) design to compare the risk of herpes zoster in a risk interval of 30 days after COVID-19 vaccination or up to the date of the second vaccine dose with a control interval remote from COVID-19 vaccination (defined as 60-90 days after the last recorded vaccination date for each individual, allowing for a 30-day washout period between control and risk intervals). A supplemental cohort analysis was used to compare the risk of herpes zoster after COVID-19 vaccination with the risk of herpes zoster after influenza vaccination among 2 historical cohorts who received an influenza vaccine in the prepandemic period (January 1, 2018, to December 31, 2019) or the early pandemic period (March 1, 2020, to November 30, 2020). Data were obtained from Optum Labs Data Warehouse, a US national deidentified claims-based database. A total of 2 039 854 individuals who received any dose of a COVID-19 vaccine with emergency use authorization (BNT162b2 [Pfizer-BioNTech], mRNA-1273 [Moderna], or Ad26.COV2.S [Johnson &amp;amp;amp; Johnson]) from December 11, 2020, through June 30, 2021, were eligible for inclusion. Individuals included in the SCRI analysis were a subset of the COVID-19\u2013vaccinated cohort who had herpes zoster during either a risk or control interval.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi221191-7\"><jats:title>Exposures<\/jats:title><jats:p>Any dose of a COVID-19 vaccine.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi221191-8\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>Incident herpes zoster, defined by <jats:italic>International Statistical Classification of Diseases and Related Health Problems, Tenth Revision <\/jats:italic>codes and a prescription of a new antiviral medication or a dose increase in antiviral medication within 5 days of diagnosis.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi221191-9\"><jats:title>Results<\/jats:title><jats:p>Among 2\u202f039\u202f854 individuals who received any dose of a COVID-19 vaccine during the study period, the mean (SD) age was 43.2 (16.3) years; 1\u202f031\u202f149 individuals (50.6%) were female, and 1\u202f344\u202f318 (65.9%) were White. Of those, 1451 patients (mean [SD] age, 51.6 [12.6] years; 845 [58.2%] female) with a herpes zoster diagnosis were included in the primary SCRI analysis. In the SCRI analysis, COVID-19 vaccination was not associated with an increased risk of herpes zoster after adjustment (incidence rate ratio,\u20090.91; 95% CI, 0.82-1.01; <jats:italic>P<\/jats:italic>\u2009=\u2009.08). In the supplementary cohort analysis, COVID-19 vaccination was not associated with a higher risk of herpes zoster compared with influenza vaccination in the prepandemic period (first dose of COVID-19 vaccine: hazard ratio [HR], 0.78 [95% CI, 0.70-0.86; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001]; second dose of COVID-19 vaccine: HR, 0.79 [95% CI, 0.71-0.88; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001]) or the early pandemic period (first dose of COVID-19 vaccine: HR, 0.89 [95% CI, 0.80-1.00; <jats:italic>P<\/jats:italic>\u2009=\u2009.05]; second dose: HR, 0.91 [95% CI, 0.81-1.02; <jats:italic>P<\/jats:italic>\u2009=\u2009.09]).<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi221191-10\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>In this study, there was no association found between COVID-19 vaccination and an increased risk of herpes zoster infection, which may help to address concerns about the safety profile of the COVID-19 vaccines among patients and clinicians.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2022.42240","type":"journal-article","created":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T16:01:18Z","timestamp":1668614478000},"page":"e2242240","source":"Crossref","is-referenced-by-count":41,"title":["Assessment of Herpes Zoster Risk Among Recipients of COVID-19 Vaccine"],"prefix":"10.1001","volume":"5","author":[{"given":"Idara","family":"Akpandak","sequence":"first","affiliation":[{"name":"F.I. Proctor Foundation, University of California, San Francisco, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Claire","family":"Miller","sequence":"additional","affiliation":[{"name":"F.I. Proctor Foundation, University of California, San Francisco, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuwei","family":"Sun","sequence":"additional","affiliation":[{"name":"F.I. Proctor Foundation, University of California, San Francisco, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin F.","family":"Arnold","sequence":"additional","affiliation":[{"name":"F.I. Proctor Foundation, University of California, San Francisco, San Francisco"},{"name":"Department of Ophthalmology, University of California, San Francisco, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Daniel","family":"Kelly","sequence":"additional","affiliation":[{"name":"F.I. Proctor Foundation, University of California, San Francisco, San Francisco"},{"name":"Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco"},{"name":"Institute for Global Health Sciences, University of California, San Francisco, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisha R.","family":"Acharya","sequence":"additional","affiliation":[{"name":"F.I. Proctor Foundation, University of California, San Francisco, San Francisco"},{"name":"Department of Ophthalmology, University of California, San Francisco, San Francisco"},{"name":"Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2022,11,16]]},"reference":[{"issue":"13","key":"zoi221191r1","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/j.vaccine.2014.10.047","article-title":"The complementary roles of phase 3 trials and post-licensure surveillance in the evaluation of new vaccines.","volume":"33","author":"Lopalco","year":"2015","journal-title":"Vaccine"},{"key":"zoi221191r2","author":"Sonani"},{"issue":"14","key":"zoi221191r3","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1001\/jama.2021.15072","article-title":"Surveillance for adverse events after COVID-19 mRNA vaccination.","volume":"326","author":"Klein","year":"2021","journal-title":"JAMA"},{"issue":"12","key":"zoi221191r4","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1056\/NEJMoa2110475","article-title":"Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting.","volume":"385","author":"Barda","year":"2021","journal-title":"N Engl J Med"},{"issue":"SI","key":"zoi221191r6","doi-asserted-by":"publisher","first-page":"SI90","DOI":"10.1093\/rheumatology\/keab345","article-title":"Herpes zoster following BNT162b2 mRNA COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series.","volume":"60","author":"Furer","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"zoi221191r7","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jdcr.2021.04.014","article-title":"Varicella-zoster virus reactivation after SARS-CoV-2 BNT162b2 mRNA vaccination: report of 5 cases.","volume":"12","author":"Rodr\u00edguez-Jim\u00e9nez","year":"2021","journal-title":"JAAD Case Rep"},{"issue":"8","key":"zoi221191r8","doi-asserted-by":"publisher","first-page":"898","DOI":"10.36849\/JDD","article-title":"Herpes zoster following COVID-19 vaccination.","volume":"20","author":"David","year":"2021","journal-title":"J Drugs Dermatol"},{"issue":"7","key":"zoi221191r9","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1111\/jocd.v20.7","article-title":"20 Post\u2013COVID-19 vaccine\u2013related shingles cases seen at the Las Vegas Dermatology clinic and sent to us via social media.","volume":"20","author":"Lee","year":"2021","journal-title":"J Cosmet Dermatol"},{"key":"zoi221191r10","doi-asserted-by":"publisher","first-page":"S130","DOI":"10.1016\/j.jaad.2007.08.046","article-title":"Herpes zoster: epidemiology, natural history, and common complications.","volume":"57","author":"Weinberg","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"zoi221191r11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/1741-7015-8-37","article-title":"The impact of herpes zoster and post\u2013herpetic neuralgia on quality-of-life.","volume":"8","author":"Johnson","year":"2010","journal-title":"BMC Med"},{"key":"zoi221191r12","doi-asserted-by":"publisher","first-page":"n1138","DOI":"10.1136\/bmj.n1138","article-title":"Covid-19 vaccination hesitancy.","volume":"373","author":"Razai","year":"2021","journal-title":"BMJ"},{"key":"zoi221191r13","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.281053"},{"issue":"8","key":"zoi221191r16","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1093\/aje\/kwu322","article-title":"A vaccine study design selection framework for the postlicensure rapid immunization safety monitoring program.","volume":"181","author":"Baker","year":"2015","journal-title":"Am J Epidemiol"},{"key":"zoi221191r17","doi-asserted-by":"publisher","first-page":"i4515","DOI":"10.1136\/bmj.i4515","article-title":"Self controlled case series methods: an alternative to standard epidemiological study designs.","volume":"354","author":"Petersen","year":"2016","journal-title":"BMJ"},{"issue":"8","key":"zoi221191r18","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.jclinepi.2005.11.012","article-title":"Four different study designs to evaluate vaccine safety were equally validated with contrasting limitations.","volume":"59","author":"Glanz","year":"2006","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"zoi221191r19","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-045343","article-title":"Impact of COVID-19 pandemic on utilisation of healthcare services: a systematic review.","volume":"11","author":"Moynihan","year":"2021","journal-title":"BMJ Open"},{"issue":"1","key":"zoi221191r20","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3122\/jabfm.2013.01.120154","article-title":"Herpes zoster knowledge, prevalence, and vaccination rate by race.","volume":"26","author":"Lee","year":"2013","journal-title":"J Am Board Fam Med"},{"issue":"11","key":"zoi221191r21","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.19433","article-title":"Oral herpes zoster infection following COVID-19 vaccination: a report of five cases.","volume":"13","author":"Fukuoka","year":"2021","journal-title":"Cureus"},{"key":"zoi221191r22","author":"Pr\u00e9ta"},{"issue":"5","key":"zoi221191r23","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1080\/14760584.2022.2044799","article-title":"Herpes zoster and simplex reactivation following COVID-19 vaccination: new insights from a Vaccine Adverse Event Reporting System (VAERS) database analysis.","volume":"21","author":"Gringeri","year":"2022","journal-title":"Expert Rev Vaccines"},{"issue":"9155","key":"zoi221191r24","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/S0140-6736(99)00623-6","article-title":"Reactivation of herpesvirus infections after vaccinations?","volume":"353","author":"Walter","year":"1999","journal-title":"Lancet"},{"issue":"1","key":"zoi221191r25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/vaccines10010001","article-title":"How does severe acute respiratory syndrome\u2013coronavirus-2 affect the brain and its implications for the vaccines currently in use.","volume":"10","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"zoi221191r26","doi-asserted-by":"publisher","first-page":"594","DOI":"10.3389\/fimmu.2019.00594","article-title":"Advances in mRNA vaccines for infectious diseases.","volume":"10","author":"Zhang","year":"2019","journal-title":"Front Immunol"},{"key":"zoi221191r27","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3389\/fcimb.2012.00122","article-title":"Toll-like receptor sensing of human herpesvirus infection.","volume":"2","author":"West","year":"2012","journal-title":"Front Cell Infect Microbiol"},{"issue":"3","key":"zoi221191r28","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.jaad.2021.11.025","article-title":"Risk of herpes zoster reactivation after messenger RNA COVID-19 vaccination: a cohort study.","volume":"87","author":"Birabaharan","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"40","key":"zoi221191r29","doi-asserted-by":"publisher","first-page":"5729","DOI":"10.1016\/j.vaccine.2021.08.088","article-title":"Oropharyngeal shedding of herpesviruses before and after BNT162b2 mRNA vaccination against COVID-19.","volume":"39","author":"Brosh-Nissimov","year":"2021","journal-title":"Vaccine"},{"issue":"1","key":"zoi221191r30","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.cmi.2021.09.018","article-title":"Real-world safety data for the Pfizer BNT162b2 SARS-CoV-2 vaccine: historical cohort study.","volume":"28","author":"Shasha","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"zoi221191r31","author":"Hertel"},{"key":"zoi221191r32","author":"Wan","year":"2022"},{"issue":"12","key":"zoi221191r33","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.40364","article-title":"Analysis of COVID-19 vaccine type and adverse effects following vaccination.","volume":"4","author":"Beatty","year":"2021","journal-title":"JAMA Netw Open"},{"key":"zoi221191r5","unstructured":"Marks P. Joint CDC and FDA statement on Johnson & Johnson COVID-19 vaccine. News release. US Food & Drug Administration. April 13, 2021. Accessed December 13, 2021. https:\/\/www.fda.gov\/news-events\/press-announcements\/joint-cdc-and-fda-statement-johnson-johnson-covid-19-vaccine"},{"key":"zoi221191r14","unstructured":"Optum Labs Data Warehouse (OLDW). The Regents of the University of California; 2022. Accessed March 2022. https:\/\/data.ucsf.edu\/research\/oldw"},{"key":"zoi221191r15","unstructured":"Centers for Medicare & Medicaid Services. Assessing the completeness of Medicare claims data for measuring COVID-19 vaccine administration. Centers for Medicare & Medicaid Services; 2021. Accessed March 22, 2022. https:\/\/www.cms.gov\/files\/document\/assessing-completeness-medicare-claims-data-measuring-covid-19-vaccine-administration.pdf"},{"key":"zoi221191r34","unstructured":"Centers for Disease Control and Prevention. COVID Data Tracker: COVID-19 vaccinations in the United States. US Department of Health and Human Services; 2022. Accessed October 13, 2022. https:\/\/covid.cdc.gov\/covid-data-tracker\/#vaccinations_vacc-total-admin-rate-total"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2798504\/akpandak_2022_oi_221191_1667839528.24171.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T16:01:23Z","timestamp":1668614483000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2798504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,16]]},"references-count":34,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.42240","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,16]]}}}